gvax lung cancer vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT00074295)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gvax lung cancer
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00074295 | Phase 2 | Mar 1, 2004 | National Cancer Institute (NCI), Southwest Oncology Group, Tulane University, University of California, Davis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Tulane University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of California, Davis | Academic/Hospital | 1 | 0 | 1 | 2004 |
4 organizations
Page 1 / 1